Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
South Korea · Delayed Price · Currency is KRW 8,080.00
-30.00 (-0.37%)
At close: Oct 2, 2026
KRX:007570 Revenue
Ilyang Pharmaceutical Co.,Ltd had revenue of 65.14B KRW in the quarter ending June 30, 2026, with 3.90% growth. This brings the company's revenue in the last twelve months to 277.96B, up 0.65% year-over-year. In the year 2025, Ilyang Pharmaceutical Co.,Ltd had annual revenue of 272.42B with 1.39% growth.
Revenue (ttm)
277.96B
Revenue Growth
+0.65%
P/S Ratio
0.52
Revenue / Employee
421.15M
Employees
660
Market Cap
144.83B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 272.42B | 3.74B | 1.39% |
| Dec 31, 2024 | 268.68B | 2.01B | 0.75% |
| Dec 31, 2023 | 266.67B | 18.90B | 7.63% |
| Dec 31, 2022 | 247.77B | 5.26B | 2.17% |
| Dec 31, 2021 | 242.51B | -100.82B | -29.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chong Kun Dang Holdings | 961.64B |
| Daewon Pharmaceutical | 614.64B |
| Jeil Pharmaceutical Co.,Ltd | 543.49B |
| Dongwha Pharm.Co.,Ltd | 513.24B |
| Kyongbo Pharmaceutical | 279.55B |
| JW Lifescience | 253.71B |
| Daihan Pharmaceutical | 216.55B |
| Hana Pharm | 139.33B |